Prime Minister Moustafa Madbouli witnessed the inking of an agreement between the international pharmaceutical company Eli Lilly and EVA Pharma within the framework of localizing industry of medical industry, especially insulin
medication.
Eva Pharma CEO Riad Armanious signed the agreement with Eli Lilly’s president and general manager for the SAMETA (South Asia, Middle East, Turkey, and Africa) region, José Antonio Alas.
On the sidelines of the inking ceremony, Board Chairman of the Egyptian Authority for Unified Procurement, medical Supply, and Management of Medical Technology, Bahaa Eddin Zidan, said the agreement falls within the framework of directives of President Abdel Fattah El Sisi to localizing medical industries, encouraging investments and boosting exports.
Zidan said the authority coordinated with EVA Pharma for the deal with Eli Lilly to maintain insulin supply to low and medium income countries.
Meanwhile, Armanious voiced happiness with inking the deal as many diabetic people in low and medium income countries face daily challenge to get their medicine.
He said the company seeks to help at least one million patients by 2030 to get their medicine.
For his part, Alas said this is the first time for Eli Lilly company to help Eva Pharma for low price insulin production.
It is expected that Eva Pharma will start distributing African-made insulin within 18 months to reach about one million people annually by 2030.